Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells.
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation and direction in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease. The founding team includes experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, who collectively have an unparalleled track record of executing safe and effective cell and gene therapy clinical trials. In addition, Tmunity’s manufacturing platform has a proven track record of success in supporting multi-center clinical studies across diverse therapeutic indications.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 31, 2019 | Series B | $75M | 1 | — | — | Detail |
Apr 19, 2018 | Series A | $35M | 2 | — | — | Detail |
Jan 23, 2018 | Series A | $100M | 2 | — | — | Detail |
Jan 12, 2016 | Series Unknown | $10M | 1 | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Sep 1, 2022
Everphone
|
Series C | $32M | B2B | — |
Dec 1, 2021
Printify
|
Series A | $5M | E-Commerce | — |
May 15, 2018
Blueground
|
Series Unknown | — | Hospitality | — |
Apr 5, 2017
Blueground
|
Series A | €23M | Hospitality | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Be The Match BioTherapies | — | Series B |
Lilly Asia Ventures | — | Series A |